Transgenic and chemically induced models such as TRAMP and MCA [26,86], which produce high TGFβ levels [87], are not susceptible to anti-tumor immunity from NCF1-NOX2-ROS deficiency but, like B16F10 [88], are sensitive to anti-TGFβ and anti-Treg treatment [87,89,90]. The gene discussed is TGFB1; the disease is neoplasm.